Syndax Pharmaceuticals (SNDX) Tops Q2 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
Tweet
Share
E-mailGet Alerts SNDX Hot Sheet
Join SI Premium – FREE
Syndax Pharmaceuticals (NASDAQ: SNDX) reported Q2 EPS of ($0.80), $0.11 better than the analyst estimate of ($0.91). Revenue for the quarter came in at $3.5 million.
For earnings history and earnings-related data on Syndax Pharmaceuticals (SNDX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- BancFirst Corp. (BANF) Tops Q3 EPS by 3c
- Qiagen posts $548M in Q3 2026 net sales amid pending EQT deal
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
